Cladribine a Safe ‘Exit Strategy’ for Stopping DMTs for MS
Medscape,
SAN DIEGO — Cladribine may be a good option for older patients with multiple sclerosis (MS) who want to discontinue their…
Annonsørinnhold kun for helsepersonell annonse «AGE MATTERS»: Utfordringer og behandlingsstrategier ved aldrende MS-populasjoner Annonnsørartikkel fra MERCK NO-MAV-00310
Dagens Medisin,
Historisk sett har multippel sklerose (MS) hovedsakelig vært ansett som en sykdom som rammer unge voksne, typisk diagnostisert…
Mavenclad (Cladribine) Approved for Active Secondary-Progressive MS
Medical Health News,
The newest option for the treatment of relapsing-remitting and active secondary-progressive multiple sclerosis (MS) offers…
Merck announces innovative MS treatment MAVENCLAD® (Cladribine Tablets) selected for rapid uptake by the Accelerated Access Collaborative
BioSpace,
– Merck today announced that Mavenclad® (cladribine 10 mg tablets) has been selected as a Rapid Uptake Product1 by the…